BR112022001702A2 - Moléculas mhc classe ii e métodos de uso das mesmas - Google Patents

Moléculas mhc classe ii e métodos de uso das mesmas

Info

Publication number
BR112022001702A2
BR112022001702A2 BR112022001702A BR112022001702A BR112022001702A2 BR 112022001702 A2 BR112022001702 A2 BR 112022001702A2 BR 112022001702 A BR112022001702 A BR 112022001702A BR 112022001702 A BR112022001702 A BR 112022001702A BR 112022001702 A2 BR112022001702 A2 BR 112022001702A2
Authority
BR
Brazil
Prior art keywords
class
amino acid
methods
molecules
hla
Prior art date
Application number
BR112022001702A
Other languages
English (en)
Portuguese (pt)
Inventor
Kenji Sugata
Naoto Hirano
Tingxi Guo
Original Assignee
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Health Network filed Critical Univ Health Network
Publication of BR112022001702A2 publication Critical patent/BR112022001702A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
BR112022001702A 2019-07-30 2020-07-29 Moléculas mhc classe ii e métodos de uso das mesmas BR112022001702A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962880509P 2019-07-30 2019-07-30
US202063029115P 2020-05-22 2020-05-22
PCT/IB2020/057174 WO2021019474A1 (en) 2019-07-30 2020-07-29 Mhc class ii molecules and methods of use thereof

Publications (1)

Publication Number Publication Date
BR112022001702A2 true BR112022001702A2 (pt) 2022-06-21

Family

ID=74230294

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022001702A BR112022001702A2 (pt) 2019-07-30 2020-07-29 Moléculas mhc classe ii e métodos de uso das mesmas

Country Status (12)

Country Link
US (1) US20220281949A1 (https=)
EP (1) EP4004033A4 (https=)
JP (1) JP7811541B2 (https=)
KR (1) KR20220052944A (https=)
CN (1) CN114502580B (https=)
AU (1) AU2020319732A1 (https=)
BR (1) BR112022001702A2 (https=)
CA (1) CA3146296A1 (https=)
IL (1) IL290231A (https=)
MX (1) MX2022001211A (https=)
TW (1) TW202118781A (https=)
WO (1) WO2021019474A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3935175A4 (en) 2019-03-04 2023-01-04 University Health Network T-LYMPHOCYTE RECEPTORS AND METHODS OF USE THEREOF
CN114450302A (zh) 2019-07-30 2022-05-06 大学健康网络 Mhc ii类分子及其使用方法
BR112022001704A2 (pt) * 2019-07-30 2022-07-05 Univ Health Network Moléculas mhc de classe ii e métodos de uso das mesmas
CN118662607A (zh) * 2023-03-15 2024-09-20 中国科学院上海巴斯德研究所 抑制过激炎性反应的蛋白及其应用
US20250074966A1 (en) * 2023-08-31 2025-03-06 Adaptive Biotechnologies Corporation Agents and methods for preventing or inhibiting adaptive immune responses associated with multiple sclerosis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4516916B2 (ja) * 2003-07-11 2010-08-04 昇志 佐藤 リビン由来のｈｌａ−ａ２４結合性癌抗原ペプチド
US20060228758A1 (en) 2004-09-13 2006-10-12 Xencor, Inc. Analysis of MHC-peptide binding interactions
GB0911566D0 (en) * 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
EP2859017B1 (en) * 2012-06-08 2019-02-20 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
US9717758B2 (en) * 2013-05-17 2017-08-01 University Of Massachusetts High-affinity DMF5 T cell receptor (TCR) variants
WO2016135363A1 (es) 2015-02-23 2016-09-01 Servicio Andaluz De Salud Método de obtención de datos útiles para predecir o pronosticar la transmisión vertical, la cronificación y/o el aclaramiento del virus de la hepatitis c
EP4212547A1 (en) * 2015-12-03 2023-07-19 Juno Therapeutics, Inc. Modified chimeric receptors and related compositions and methods
WO2017106684A2 (en) * 2015-12-17 2017-06-22 Janssen Biotech, Inc. Antibodies specifically binding hla-dr and their uses
GB201604492D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
US12187781B2 (en) * 2018-08-01 2025-01-07 Regents Of The University Of Minnesota Co-receptor affinity enhanced major histocompatibility class II molecules

Also Published As

Publication number Publication date
JP7811541B2 (ja) 2026-02-05
CN114502580B (zh) 2025-10-17
EP4004033A1 (en) 2022-06-01
KR20220052944A (ko) 2022-04-28
IL290231A (en) 2022-03-01
US20220281949A1 (en) 2022-09-08
WO2021019474A1 (en) 2021-02-04
EP4004033A4 (en) 2023-12-06
CN114502580A (zh) 2022-05-13
MX2022001211A (es) 2022-05-03
AU2020319732A1 (en) 2022-03-03
CA3146296A1 (en) 2021-02-04
TW202118781A (zh) 2021-05-16
JP2022542448A (ja) 2022-10-03

Similar Documents

Publication Publication Date Title
BR112022001702A2 (pt) Moléculas mhc classe ii e métodos de uso das mesmas
BR112022001710A2 (pt) Moléculas mhc de classe ii e métodos de uso das mesmas
BR112018000477A2 (pt) proteína de ligação de imunoglobulina não natural, composição, uso da proteína de ligação de ig não natural, método de purificação de afinidade de imunoglobulinas, método de geração de uma proteína de ligação de imunoglobulina não natural, molécula de ácido nucleico, vetor, célula hospedeira ou um hospedeiro não humano, e método para a produção de uma proteína de ligação de imunoglobulina não natural
CY1122576T1 (el) Ανθρωπινα αντισωματα που δεσμευουν το γονιδιο-3 ενεργοποιησης λεμφοκυτταρων (leg-3), και χρησεις εξ' αυτων
AR060583A1 (es) Anticuerpo de c- kit humanizado
BR112012017124B8 (pt) método para produzir e para purificar um multímero polipeptídico
BR122021020829B8 (pt) Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada
MX2013003884A (es) Metodo para activar celulas auxiliares.
BRPI0111191B8 (pt) moléculas mutantes de ctla4 solúveis, método para sua produção e seus usos
BR112021021912A2 (pt) Nova nuclease omni-50 crispr
BR112022001704A2 (pt) Moléculas mhc de classe ii e métodos de uso das mesmas
AR080942A1 (es) Produccion de proteinas heteromultimericas
BRPI0612273C1 (pt) anticorpo de ligação a il-1 beta ou fragmento de ligação a il-1 beta do mesmo, ácido nucleico, vetor, e, composição
BRPI0515649B8 (pt) Processo para preparação de composições de anticorpo monoclonal altamente concentradas
BR112021018734A2 (pt) Receptores de células t e métodos de uso destes
BR112021017464A2 (pt) Receptores de células t e métodos de uso dos mesmos
BR112021012240A2 (pt) Terapia de gene-célula-tronco hematopoiética para síndrome wiskott-aldrich
MX2022001204A (es) Métodos de identificación de receptores de linfocitos t.
BR112021017486A2 (pt) Receptores de células t e métodos de uso dos mesmos
BR112021017479A2 (pt) Receptores de células t e métodos de uso dos mesmos
BR112021017491A2 (pt) Receptores de células t e métodos de uso dos mesmos
BR112022015897A2 (pt) Receptores de célula t restritos à classe i de hla contra ras com mutação de g12v
BR112021017505A2 (pt) Receptores de células t e métodos de uso dos mesmos
MX2023002602A (es) Composicion para inmunoterapia.
BR112022015529A2 (pt) Receptor de antígeno quimérico, célula, composição, métodos, molécula de ácido nucleico, vetor, célula hospedeira e kit